Company Overview
Annexon, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of therapeutic medicines specifically designed for the treatment of inflammatory-related diseases. Within the broader Healthcare sector, the company focuses its operational efforts on the specialized industry of Biotechnology, targeting the advancement of novel pharmacological solutions for patients with specific conditions. The company's current market capitalization stands at $745.28M, supported by a workforce of 99 employees, while reported revenue for the trailing twelve months is N/A. The absence of reported revenue figures alongside the significant market cap indicates that the company is likely in an early-stage development phase where valuation is driven by pipeline potential and asset discovery rather than established commercial sales streams. This financial structure suggests the company is allocating capital toward research and clinical trials, such as the Phase 3 trial for its lead candidate ANX005, rather than generating immediate commercial cash flow from product sales.
Financial Health
The company's financial performance for the trailing twelve months reflects a net income of $-208,880,992 and an EBITDA of $-216,468,000, while revenue remains unreported in the available data. The substantial gap between the reported net income loss and the EBITDA loss highlights a significant tax benefit or non-operating income component that partially offsets the operational burn rate, though the overall financial position remains in a deficit state. Free cash flow stands at $-93,057,504, indicating that the company is consuming cash reserves to fund its clinical operations and research initiatives rather than generating surplus liquidity from current activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which is typical for pre-revenue biotechnology firms but signifies that the company has not yet achieved commercial profitability or revenue recognition sufficient to calculate meaningful margins. On the balance sheet, the company holds $188.72M in cash against $26.94M in debt, resulting in a debt-to-equity ratio of 16.69, which suggests a highly leveraged capital structure relative to equity, though the substantial cash cushion provides a buffer against operational obligations. Liquidity is robust, evidenced by a current ratio of 4.42, which indicates that the company possesses more than four times the current assets necessary to cover its short-term liabilities without immediate refinancing. Return on Equity is reported at -84.0% and Return on Assets at -45.0%, revealing that management has not yet generated positive returns on the capital invested by shareholders or utilized in assets, a common characteristic of clinical-stage companies burning through capital to reach commercial milestones.
Valuation Assessment
Valuation multiples for Annexon, Inc. present a mixed picture typical of high-risk biotechnology assets, with a trailing P/E ratio listed as N/A due to negative earnings and a forward P/E of -4.20. The difference between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in a significant turnaround in earnings trajectory or a reliance on future financing rather than current profitability. The price-to-book ratio is 3.57, indicating that the market is valuing the company at a premium of over three times its book value, likely reflecting the perceived potential value of its intellectual property and pipeline candidates rather than tangible assets. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and an EV/EBITDA of -2.02, further underscore the difficulty in applying traditional multiple-based valuation models to a company with no sales and negative earnings. Regarding trading range, the 52-week high is $7.18 and the 52-week low is $1.28, providing a benchmark for the volatility and investor sentiment surrounding the stock over the past year. The beta value of 1.18 indicates that the stock's price volatility is 18% higher than the broader market, suggesting that price movements will likely be more pronounced during periods of market fluctuation.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, reflecting the company's status as a pre-revenue entity where historical growth metrics are not yet applicable or calculable. In the absence of positive earnings growth to support a payout, the company does not distribute dividends, resulting in a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all available capital and retained earnings directly into research and development activities to advance its clinical candidates rather than returning value to shareholders through dividend payments. The overall growth and income profile is characterized by high operational risk and zero current income distribution, relying entirely on the successful advancement of its drug candidates to eventually transition to a revenue-generating and profitable business model.